Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/722
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMulligan, Stephenen
dc.contributor.authorKarlsson, Karinen
dc.contributor.authorStrömberg, Mattsen
dc.contributor.authorJønsson, Viggoen
dc.contributor.authorGill, Devinderen
dc.contributor.authorHammerström, Jensen
dc.contributor.authorHertzberg, Marken
dc.contributor.authorMcLennan, Rogeren
dc.contributor.authorUggla, Bertilen
dc.contributor.authorNorman, Johnen
dc.contributor.authorWalvik, Jonasen
dc.contributor.authorSundström, Gunnelen
dc.contributor.authorHemming, Johanssonen
dc.contributor.authorBrandberg, Yvonneen
dc.contributor.authorLiliemark, Janen
dc.contributor.authorJuliusson, Gunnaren
dc.date.accessioned2015-06-25T04:34:58Zen
dc.date.available2015-06-25T04:34:58Zen
dc.date.issued2014en
dc.identifier.govdoc00705en
dc.identifier.issn1042-8194en
dc.identifier.urihttp://hdl.handle.net/11054/722en
dc.description.abstractWe conducted a randomized phase III trial to compare the efficacy and safety of two purine analogs, cladribine and fludarabine, with high-dose chlorambucil, in patients with previously untreated chronic lymphocytic leukemia (CLL). Between 1997 and 2004, 223 patients with CLL were randomly assigned to cladribine, fludarabine or chlorambucil, for six cycles of therapy with frequent health-related quality of life assessments. There was no statistical difference for the primary endpoint of overall response with cladribine (70%), fludarabine (67%) and chlorambucil (59%), or complete remission (12%, 7% and 8%), respectively. However, the median progression-free survival (25, 10, 9 months) and median time to second treatment (40, 22, 21 months) were superior with cladribine. There was no significant difference in overall survival (96, 82 and 91 months), nor in toxicity or HRQoL assessments. Monotherapy with cladribine gives superior PFS and longer response duration than fludarabine and chlorambucil as first-line treatment of CLL.en
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2015-06-23T03:02:02Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2015-06-25T04:34:58Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2015-06-25T04:34:58Z (GMT). No. of bitstreams: 0 Previous issue date: 2014en
dc.publisherInformaen
dc.titleCladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.en
dc.typeJournal Articleen
dc.type.specifiedArticleen
dc.bibliographicCitation.titleLeukemia & Lymphomaen
dc.bibliographicCitation.volume55en
dc.bibliographicCitation.issue12en
dc.bibliographicCitation.stpage2769en
dc.bibliographicCitation.endpage2777en
dc.publisher.placeLondon, United Kingdomen
dc.subject.healththesaurusLYMPHOID LEUKEMIAen
dc.subject.healththesaurusCHEMOTHERAPEUTIC APPROACHESen
dc.subject.healththesaurusPHARMACOTHERAPEUTICSen
dc.subject.healththesaurusCLLen
dc.subject.healththesaurusLEUKEMIAen
dc.date.issuedbrowse2014-01-01en
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.